Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Psychedelic Treatment of Addiction (April/May/June) | 2024

View Archived Issues

Learning Objectives, Psychedelic Treatment of Addiction, CATR, April/May/June 2024

April 1, 2024

After reading these articles, you should be able to...

Treating Opioid Use Disorder During Pregnancy

April 1, 2024

Ariadna Forray, MD and Noah Capurso, MD

As the overall prevalence of opioid use disorder has increased, so to has the prevalence of opioid use during pregnancy. Opioid use during pregnancy can put both your patient and the baby at risk, making proper treatment with MOUD essential. In this article, we outline the special considerations for the treatment of OUD during pregnancy and discuss how to prescribe MOUD safely.

Psychedelics and Addiction

April 1, 2024

Snehal Bhatt, MD

Dr. Bhatt outlines the latest developments in therapeutic uses of psychedelic medications. He highlights the great opportunities as well as the potential drawbacks. He details some of his own work in the use of psilocybin for the treatment of alcohol use disorder and advises clinicians how to discuss psychedelics with their patients.

Ketamine Use and Misuse

April 1, 2024

Keith A. Trujillo, PhD

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.

Three Buprenorphine Dosing Strategies When Transitioning From Other Opioids

April 1, 2024

Monthe Kofos, DO and Noah Capurso, MD

The process of starting a patient on buprenorphine, called an induction, can be a bit tricky and puts a patient at risk of a precipitated opioid withdrawal. In this article, we discuss the three most common buprenorphine induction approaches, review the pros and cons of each, and include straightforward guidance that will help you perform a successful buprenorphine induction for your patients.

Buprenorphine versus Methadone for Prescription Opioid Use Disorder

April 1, 2024

Richard Moldawsky, MD

Methadone treatment for OUD typically comes with a high level of supervision whereas buprenorphine is often flexibly dosed and taken at home. Here researchers wanted to know how patients of a closely supervised methadone clinic compared with those taking buprenorphine prescribed in an office setting. The findings might surprise you.

Opioid Use Disorder Treatment During the Peripartum Period

April 1, 2024

Gregory Nikogosyan, DO

The last high-quality head-to-head comparison of buprenorphine and methadone during pregnancy was the MOTHER trial, which was published nearly 15 years ago. Here, researchers revisited the question of which medication is better to use in pregnancy in this large, carefully done, retrospective study. The results make a compelling case for buprenorphine.